ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SUPN vs BHVN // 10Y YIELD & FRED MACRO BETA

Supernus Pharmaceuticals Inc. (NASDAQ) VS. Biohaven Ltd. (NYSE) • 15-METRIC TALLY: SUPN 3 — BHVN 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. BHVN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SUPN BHVN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 89.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -4.50% -35.00% +30.50 SUPN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 1.89% -24.50% +26.39 SUPN /fcf-yield <GO>
Operating Margin -8.70% — — TIE /operating-margins <GO>
Net Profit Margin -5.40% — — TIE /net-margins <GO>
Revenue Growth (YoY) 8.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.84 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 SUPN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.5 65.4 -14.90 BHVN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE 0.88 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 22.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.43B $2.49B -$58.7M BHVN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SUPN REV BHVN REV SUPN GROSS % BHVN GROSS % SUPN FCF BHVN FCF
FY 2025 $719.0M $0 89.6% — $46.0M -$610.2M
FY 2024 $661.8M $0 88.2% — $171.2M -$586.5M
FY 2023 $607.5M $0 — — $83.7M -$331.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
BHVN // BETA —